Nutraplus India FY25 loss narrows; audit doubts survival

Filing highlights and why it matters

Nutraplus India Limited has reported another loss-making year, while its auditors have raised doubts about the company’s ability to continue as a going concern. For FY25 (year ended March 31, 2025), the company posted a net loss of ₹0.05 crore, slightly lower than the FY24 net loss of ₹0.06 crore. The improvement is marginal and comes against a backdrop of negative working capital, negative cash flows, and an entirely eroded net worth.

The disclosures also point to long-standing financial and governance challenges, including a loan default and weaknesses in controls and compliance. Separately, the company’s unaudited standalone results for Q2 FY26 (quarter ended September 30, 2025) showed lower revenue and sharply higher losses year-on-year. The latest limited review notes listing-related non-compliance and delays in providing information to auditors, which the auditors said impaired their review.

FY25 results: losses narrow, but stress persists

In its FY25 results, Nutraplus India reported a net loss of ₹0.05 crore (₹5,00,961). In FY24, the net loss was ₹0.06 crore (₹6,15,824). While the loss narrowed slightly, the filing describes a balance sheet under pressure, with net worth described as severely eroded.

The company also disclosed negative working capital and negative cash flow, indicating it does not generate enough cash to comfortably meet near-term obligations from operations. The auditor’s qualification, as presented in the filing, adds to the risk perception because it ties financial stress to the company’s ability to continue as a going concern.

Auditor flags going-concern uncertainty

The auditors issued a qualified opinion highlighting “substantial doubt” about Nutraplus India’s ability to continue as a going concern. The filing attributes this to a combination of factors, including eroded net worth and negative cash flows. It also points to governance lapses and inadequate internal controls as part of the broader set of concerns.

A going-concern warning does not by itself mean operations will stop immediately, but it signals that the auditor sees material uncertainty around the company’s ability to meet obligations and sustain operations without corrective actions. For investors, this typically increases focus on liquidity, compliance standing, and any credible steps announced by the company to stabilize finances.

Loan default and accumulated losses add to the overhang

The filing notes accumulated losses of ₹62.57 crore as of March 31, 2025. It also states that the company defaulted on a ₹76.24 crore loan from Saraswat Bank up to February 18, 2020. These disclosures point to financial stress that has persisted for years.

The company’s net worth has been stated as entirely eroded, and it operates with negative working capital. Together, these factors increase reliance on external support, restructuring, or resolution actions, and also heighten scrutiny from lenders, auditors, and regulators.

Q2 FY26: revenue slips, loss expands sharply

Nutraplus India’s unaudited standalone results for Q2 FY26 showed Revenue from Operations of ₹0.98 crore, down from ₹1.17 crore in Q2 FY25. Total Income was also ₹0.98 crore, compared with ₹1.17 crore a year earlier.

The net loss widened significantly to ₹2.09 crore in Q2 FY26, from ₹0.04 crore in Q2 FY25. The company reported EPS (basic and diluted) of ₹-0.11 for the quarter.

For the half-year ended September 30, 2025 (YTD FY26), Revenue from Operations declined to ₹1.96 crore from ₹2.48 crore in YTD FY25. Over the same period, the net loss widened to ₹2.05 crore, from ₹0.65 crore in the prior year.

Limited review report cites non-compliance and delayed information

Alongside the Q2 FY26 numbers, auditors Raman S. Shah & Associates issued a Qualified Limited Review Report. The report highlighted non-compliance with listing requirements, including the timely submission of the limited review report and quarterly results.

The auditors also stated that the company failed to provide necessary financial data in a timely manner, which “significantly impaired” their ability to conduct a comprehensive review. In practice, such remarks increase concern about the reliability and completeness of reported information and can intensify regulatory and exchange scrutiny.

Balance sheet snapshot: negative equity and heavy borrowings

As of September 30, 2025, the company disclosed Total Assets of ₹499.76 crore and Total Equity of ₹-571.52 crore, indicating a deeply negative net worth position. Total Borrowings (non-current plus current) were reported at ₹1,017.87 crore. Cash and cash equivalents stood at ₹0.02 crore, implying net debt of about ₹1,017.85 crore based on the figures provided.

The filing also referenced an estimated current ratio of around 0.046, pointing to an extreme liquidity crunch. The company flagged a fundamental operational challenge as well, citing the inability to operate without its core property, plant, and equipment.

What the disclosures mean for shareholders and the stock

Nutraplus India is listed on the BSE (524764) and operates in pharmaceuticals, including APIs. Market data in the provided text indicates a market capitalisation of ₹7.16 crore and a current price of ₹2.10, alongside a negative P/E (TTM) of -42.00 and EPS (TTM) of -0.05.

The combination of continuing losses, negative equity, high borrowings, very low cash, and audit qualifications raises risk levels for shareholders. The specific mention of listing-related non-compliance also matters because exchanges can seek clarifications, impose penalties, or require tighter disclosures, depending on facts and timelines.

Key figures from the disclosures

Conclusion

Nutraplus India’s FY25 loss narrowed slightly, but audit qualifications, going-concern uncertainty, and a history of default and accumulated losses continue to dominate the narrative. The Q2 FY26 results added fresh pressure, with lower revenue and a sharply higher loss, alongside a qualified limited review citing delays and listing compliance issues.

Near-term attention will likely remain on the company’s regulatory compliance track record, the quality and timeliness of disclosures, and any concrete steps it takes to address liquidity, controls, and its ability to operate sustainably.